Total Funding
35
48
Total FundingPost-IPO Equity raised
Growth Score
-7 pts
Heat Score
9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
74325
Eyenovia is a biopharmaceutical company that provides a portfolio of next generation topical eye treatments.
Luke Clauson: VP, R&D and EngineeringPast Role: Dextera Surgical, Director of Engineering- Lee Kramm: Consultant, Regulatory Affairs
About the Company
Eyenovia is a biopharmaceutical company that provides portfolio of next generation topical eye treatments. It is a clinical stage, ophthalmic biopharmaceutical company that transforms the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others.
Eyenovia’s breakthrough
piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics.
Eyenovia was founded in 2014.
